Skip to main content
Mark Awad, MD, Oncology, New York, NY

MarkMAwadMD

Oncology New York, NY

Clinical Fellow in Medicine, Brigham and Women's Hospital

Overview of Dr. Awad

Dr. Mark Awad is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, and Dana-Farber Cancer Institute. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 9 years. He is one of 376 doctors at Brigham and Women's Hospital and one of 453 doctors at Dana-Farber Cancer Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 2008

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2024 - 2026
  • MA State Medical License
    MA State Medical License 2012 - 2025
  • NJ State Medical License
    NJ State Medical License 2024 - 2025
  • NH State Medical License
    NH State Medical License 2024 - 2024
  • RI State Medical License
    RI State Medical License 2020 - 2020
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Authors’ Response  
    Matthew P Cheng, Mark M Awad, Journal of Thoracic Oncology

Lectures

  • Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC). 
    2019 ASCO Annual Meeting - 6/1/2019
  • Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
  • ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non small cel... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

  • Authors’ ResponseOctober 2018

Press Mentions

  • Questions to Ask if You've Been Diagnosed with Lung Cancer
    Questions to Ask if You've Been Diagnosed with Lung CancerNovember 1st, 2024
  • New Study to Address Cancer Treatment Resistance for People Who Are KRAS Positive
    New Study to Address Cancer Treatment Resistance for People Who Are KRAS PositiveNovember 30th, 2022
  • Opdivo May Bring Survival Boost for Lung Cancer Patients
    Opdivo May Bring Survival Boost for Lung Cancer PatientsApril 13th, 2022
  • Join now to see all